TransMedics Group, Inc.

As of June 30, 2026, TransMedics Group, Inc. carries a market capitalization of 39.82B, placing it among publicly traded companies globally. Its enterprise value stands at 46.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TransMedics Group, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, TransMedics Group, Inc. has 34.63M shares outstanding.

As of June 30, 2026, TransMedics Group, Inc. trades at a trailing price-to-earnings ratio of 14.89. The price-to-sales ratio is 3.38, and the price-to-book ratio stands at 4.40.

As of June 30, 2026, TransMedics Group, Inc. trades at an EV/EBITDA multiple of 22.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.77 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 46.73B versus a market cap of 39.82B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TransMedics Group, Inc. maintains a current ratio of 6.62, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 167.50, indicating elevated leverage, while an interest coverage ratio of 5.56 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. posted a return on equity (ROE) of 36.28, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 12.88, measuring how efficiently the asset base is converted into earnings. The company generates approximately 13.65M in revenue per employee across its workforce of 855.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.94 indicates how many times TransMedics Group, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. recorded an income tax benefit of -1.38B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.27B, leaving 2.65B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 14, 2026, TransMedics Group, Inc.'s stock has declined approximately 30.02% over the past 52 weeks.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. generated 11.68B in revenue and converted that into 2.65B in net income, yielding earnings per share of 66.85. EBITDA reached 2.06B, while operating income came in at 1.43B.

As of June 30, 2026, TransMedics Group, Inc. holds 8.26B in cash and equivalents against 15.16B in total debt, resulting in a net debt position of 722.07M. Total book value stands at 9.05B, with working capital of 9.66B providing operational flexibility.

TransMedics Group, Inc. produced 2.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.17B in capital expenditures, free cash flow totaled 1.38B - equivalent to 40.23 per share.

Over the twelve months ended June 30, 2026, TransMedics Group, Inc. posted a gross margin of 58.69, reflecting its pricing power and cost economics. The operating margin of 12.21 and net profit margin of 22.69 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.50, meaning TransMedics Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, TransMedics Group, Inc. has an Altman Z-Score of 2.30, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.